Retinoblastoma

What is Retinoblastoma?

Retinoblastoma is a rare cancer that develops in the retina, the light-sensitive tissue at the back of the eye. This malignancy primarily affects infants and young children, typically appearing before age 5. Retinoblastoma occurs in approximately 1 in 15,000 to 20,000 births, making it the most common primary eye cancer in children. While the diagnosis can be overwhelming for families, early detection and modern treatments have dramatically improved outcomes, with cure rates exceeding 95% in developed countries.

Key statistics

Symptoms

Primary symptoms: Leukocoria (white pupil), strabismus, vision problems, eye pain, red or irritated eyes

The most characteristic early sign of retinoblastoma is leukocoria, also called “cat’s eye reflex” or “white pupil.” Parents often first notice this when the affected pupil appears white or yellowish in photographs taken with flash, rather than the normal red-eye reflection. Strabismus (crossed eyes or misaligned eyes) is another common early symptom that may prompt medical evaluation.

As the tumor grows, children may experience vision problems in the affected eye, though young children cannot typically communicate these changes. Other symptoms can include persistent eye pain, redness, or irritation that doesn’t respond to typical treatments. In advanced cases, the eye may appear enlarged, or there may be visible changes to the iris. Some children may show sensitivity to light or excessive tearing.

Submit Your Paper

Parents should note that symptoms typically affect one eye initially, though bilateral retinoblastoma can present with symptoms in both eyes simultaneously. Early symptoms are often subtle, emphasizing the importance of regular pediatric eye examinations.

Causes and risk factors

Retinoblastoma is caused by mutations in the RB1 gene, which normally acts as a tumor suppressor by controlling cell division in retinal cells. The condition follows two distinct patterns: hereditary (40% of cases) and non-hereditary or sporadic (60% of cases).

Hereditary retinoblastoma follows an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene from either parent is needed to cause the disease. These cases are more likely to be bilateral (affecting both eyes) and tend to occur at a younger age. Children with hereditary retinoblastoma also have an increased risk of developing other cancers later in life.

Sporadic retinoblastoma results from new mutations that occur during early development and are not inherited from parents. These cases are typically unilateral (affecting one eye) and are not passed on to future generations.

The primary risk factor is having a parent with retinoblastoma or a family history of the condition. However, about 90% of cases occur in families with no previous history of the disease. Advanced parental age may slightly increase risk, but this association is not definitively established.

Prevention

There is no way to prevent retinoblastoma from occurring, as it results from genetic mutations that happen during development. However, genetic counseling and testing can help families understand their risk and make informed reproductive decisions.

For families with a history of retinoblastoma, genetic testing can determine if parents carry RB1 mutations. Carrier frequency in the general population is extremely low, estimated at less than 1 in 30,000 individuals. Prenatal genetic testing is available for families with known hereditary retinoblastoma, though many families choose to proceed with pregnancy and focus on early detection strategies.

The most effective prevention strategy is early detection through regular eye examinations. The American Academy of Pediatrics recommends that all newborns receive eye examinations, with additional screening for children at increased risk due to family history.

Complications

Without treatment, retinoblastoma is universally fatal as the cancer spreads beyond the eye to the brain and other organs. Even with treatment delays, the cancer can metastasize, significantly reducing survival rates.

Long-term complications may include vision loss or complete loss of the affected eye, which can impact depth perception and overall visual function. Children who undergo enucleation (eye removal) require prosthetic eyes and ongoing adjustments as they grow.

Individuals with hereditary retinoblastoma face an increased lifetime risk of developing secondary cancers, including osteosarcoma, soft tissue sarcomas, and melanoma. This risk is further elevated in those who receive radiation therapy. Regular oncological surveillance is essential throughout life for hereditary cases.

Treatment-related complications can include cataracts, retinal detachment, and growth abnormalities of facial bones if radiation therapy is used. Modern treatment approaches aim to minimize these long-term effects while maintaining cure rates.

Diagnosis

Diagnosis typically begins with a comprehensive ophthalmological examination under anesthesia, allowing detailed visualization of the retina. Fundoscopy reveals the characteristic appearance of retinoblastoma tumors, which appear as white or cream-colored masses.

Imaging studies include ultrasound of the eyes, magnetic resonance imaging (MRI) of the brain and orbits, and sometimes computed tomography (CT) scans, though CT is used sparingly due to radiation exposure concerns. These studies help determine tumor size, location, and extent of disease.

Genetic testing for RB1 mutations is crucial for determining inheritance patterns and guiding family counseling. Blood tests can detect germline mutations, while tumor tissue analysis may reveal somatic mutations in sporadic cases.

Unlike many cancers, biopsy is contraindicated in retinoblastoma due to the risk of spreading cancer cells. Diagnosis relies primarily on clinical appearance and imaging findings. Cerebrospinal fluid analysis may be performed if there’s concern for central nervous system spread.

Treatment

Treatment approaches depend on tumor size, location, laterality, and whether the cancer has spread beyond the eye. Modern therapy aims to preserve life, save the eye when possible, and maintain vision.

Chemotherapy is often the first-line treatment, using combinations of drugs including carboplatin, vincristine, and etoposide. Intra-arterial chemotherapy delivers drugs directly to the eye through the ophthalmic artery, allowing higher local concentrations with reduced systemic exposure.

Local therapies include laser photocoagulation, cryotherapy (freezing treatment), and thermotherapy (heat treatment) for smaller tumors. Plaque radiotherapy uses radioactive discs placed on the eye’s surface to target specific tumor areas.

Enucleation (surgical eye removal) may be necessary for large tumors or when other treatments have failed. Modern prosthetic eyes provide excellent cosmetic results.

External beam radiation therapy is used less frequently due to secondary cancer risks but may be necessary for advanced cases or when other treatments are unsuccessful.

Prognosis

The prognosis for retinoblastoma is excellent when detected early and treated appropriately. In developed countries, cure rates exceed 95%, with most children surviving to adulthood. Early-stage, unilateral disease has the best outcomes, with high rates of eye preservation and useful vision.

Bilateral retinoblastoma generally has a good prognosis for survival, though vision preservation may be more challenging. Advanced disease that has spread beyond the eye significantly reduces survival rates, emphasizing the importance of early detection.

Quality of life is generally excellent for retinoblastoma survivors, though those with bilateral disease may have visual impairments requiring educational and occupational accommodations. Children who lose one eye typically adapt well and can participate in most normal activities.

Long-term survival requires ongoing surveillance for secondary cancers in hereditary cases, with the risk being highest in the first two decades after initial treatment.

Quality of life

Children treated for retinoblastoma can expect to lead full, active lives. Those who retain vision in at least one eye typically have minimal functional limitations. Educational support may be needed for children with significant visual impairment, but many attend mainstream schools successfully.

Physical activity is generally unrestricted, though children with prosthetic eyes may need protective eyewear for contact sports. Swimming and most recreational activities are safe and encouraged.

Psychological support helps families cope with the diagnosis and treatment process. Many children adapt remarkably well to visual changes, and peer support through patient organizations can be invaluable.

Regular ophthalmological care is essential for monitoring the remaining eye and detecting any late treatment effects. Occupational therapy may help children develop adaptive strategies for daily activities if needed.

Mental health support addresses potential anxiety about cancer recurrence and helps families maintain a positive outlook while remaining vigilant about follow-up care.

Pregnancy and fertility

Retinoblastoma treatment typically does not affect fertility in survivors. However, genetic counseling is crucial for survivors planning families, as hereditary retinoblastoma carries a 50% risk of transmission to each child.

Pregnancy in retinoblastoma survivors requires standard obstetric care, though genetic counseling and prenatal testing options should be discussed. Some survivors may benefit from preimplantation genetic diagnosis if they choose in vitro fertilization.

For women who develop retinoblastoma during pregnancy (extremely rare), treatment decisions require careful coordination between oncologists, ophthalmologists, and maternal-fetal medicine specialists to balance maternal and fetal safety.

Children

Since retinoblastoma primarily affects children, pediatric considerations are central to all aspects of care. Treatment requires specialized pediatric oncology and ophthalmology teams experienced in managing young patients.

Parents play crucial roles in monitoring for symptoms and ensuring compliance with treatment and follow-up schedules. Educational resources help families understand the condition and treatment process in age-appropriate ways.

Siblings of affected children may need genetic testing and psychological support. Schools should be informed about any visual limitations to ensure appropriate accommodations.

Long-term follow-up includes monitoring for secondary cancers, vision changes, and developmental needs related to visual impairment.

When to see a doctor

Seek immediate medical attention if you notice a white or yellowish reflection in your child’s pupil, especially in photographs taken with flash. Any persistent eye misalignment, vision problems, or eye pain in young children warrants prompt evaluation.

Urgent referral to pediatric ophthalmology is needed for any suspected retinoblastoma symptoms. Early diagnosis significantly improves outcomes and treatment options.

Regular pediatric checkups should include basic eye examinations, and any concerns about vision or eye appearance should be addressed promptly with healthcare providers.

Regional context

Specific prevalence data for retinoblastoma in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited in published literature. The condition likely occurs at similar rates to global estimates, but access to specialized care and outcomes may vary.

We invite healthcare professionals and researchers from these regions to contribute data and insights about retinoblastoma prevalence, treatment access, and outcomes to the Global Medical Journal to better understand regional patterns and needs.

Research and clinical trials

Current research focuses on improving eye preservation rates, reducing treatment toxicity, and developing targeted therapies. Novel drug delivery methods, including sustained-release implants and nanoparticle delivery systems, show promise for reducing systemic chemotherapy exposure.

Immunotherapy approaches are being investigated, as retinoblastoma may be susceptible to certain immune-based treatments. Gene therapy research aims to restore normal RB1 function in cancer cells.

Clinical trials are available through ClinicalTrials.gov, with studies investigating new chemotherapy combinations, radiation techniques, and supportive care measures. Participation in research helps advance treatment options for future patients.

Frequently asked questions

Will my child go blind from retinoblastoma?

Many children retain useful vision, especially if diagnosed early and if only one eye is affected. Even bilateral cases may preserve vision in at least one eye with modern treatments.

Is retinoblastoma hereditary?

About 40% of cases are hereditary, following an autosomal dominant pattern. Genetic testing can determine if the condition is hereditary and inform family planning decisions.

Can retinoblastoma spread to other parts of the body?

If untreated, retinoblastoma can spread beyond the eye to the brain and other organs. However, early detection and treatment prevent metastasis in the vast majority of cases.

What does a prosthetic eye look like?

Modern prosthetic eyes are custom-made to match the unaffected eye and provide excellent cosmetic results. Most people cannot tell that someone has a prosthetic eye.

Will my child need treatment for life?

Active treatment typically lasts months to a few years, but survivors require lifelong monitoring for recurrence and secondary cancers, especially in hereditary cases.

Support and resources

International organizations:
– World Health Organization (WHO): www.who.int
– Orphanet: www.orpha.net
– EURORDIS (European Organisation for Rare Diseases): www.eurordis.org
– National Organization for Rare Disorders (NORD): rarediseases.org

Retinoblastoma-specific organizations:
– World Eye Cancer Hope: www.wechope.org
– Childhood Eye Cancer Trust: www.chect.org.uk
– Retinoblastoma International: www.retinoblastoma.net

Related conditions

Osteosarcoma – Secondary cancer risk in hereditary retinoblastoma
Li-Fraumeni syndrome – Another cancer predisposition syndrome
Bilateral retinoblastoma – Specific form affecting both eyes
Coats disease – Important differential diagnosis
Persistent hyperplastic primary vitreous – Another cause of leukocoria

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.